H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 13/05/2026 BST			5-day change	1st Jan Change
41.38 ^DKK	-0.43%		-3.90%	-4.12%

05-13	H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation
05-13	Nordea raises Lundbeck price target to DKK 57 (55), reiterates Buy	FW

Transcript : H. Lundbeck A/S - Shareholder/Analyst Call

Published on 03/18/2026 at 10:50 am GMT - Modified on 03/18/2026 at 03:50 pm GMT

S&P Capital IQ

Presenter Speech
Ilse Wenzel (Executives)

Good morning, and welcome. On behalf of the Board of Directors, it's my great pleasure to welcome you today to Lundbeck's Annual General Meeting. And it's

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about H. Lundbeck A/S

05-13	H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation
05-13	Nordea raises Lundbeck price target to DKK 57 (55), reiterates Buy	FW
05-13	DNB Carnegie raises Lundbeck price target to DKK 54 (53), reiterates Buy	FW
05-12	H. Lundbeck A/S Raises Earning Guidance for Full Year of 2026	CI
05-12	H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	Lundbeck beats expectations (Update)	FW
05-12	Lundbeck posts growth in revenue and adjusted EBITDA	FW
05-12	Lundbeck raises 2026 guidance	FW
05-12	H. Lundbeck forecasts adjusted EBITDA growth of 8-14 percent (previously 4-12)	FW
05-12	H. Lundbeck A/S raises guidance	FW
04-28	SEB raises Lundbeck price target to DKK 46 (43), reiterates Hold	FW
04-27	UBS raises Lundbeck price target to DKK 44 (42), reiterates Neutral	FW
04-20	Lundbeck highlights cognitive improvements in migraine treatment according to study	FW
04-20	Lundbeck highlights cognitive improvements in migraine according to study	FW
04-20	Lundbeck highlights cognitive improvements in migraine treatment according to study	FW